Skip to main content

Pharma continues to drive Lonza growth

Lonza has reported 7.7% growth in sales in constant currency terms during 1H 2020 to CHF 3,074 million, with a core EBITDA margin of 29.1%. This, as in 2019, was largely driven by the Lonza Pharma Biotech & Nutrition (LBPN) segment, which had 10.8%3 sales growth and a margin of 34.1%.

Wacker starts ‘shaping the future’

Wacker Chemie has announced its initial plans for its ‘Shape the Future’ efficiency programme in anticipation of what CEO Rudolf Staudigl called “a harsher competitive environment”.

Lonza swings to pharma

Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future.
Subscribe to results

 

 

 

AMRI banner advert